![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
VYNE Therapeutics Inc | NASDAQ:VYNE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.14 | 2.70 | 0 | 01:00:00 |
| |
Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to Be Held on
December 13, 2023 at 685 Route 202/206 N., Suite 301, Bridgewater, New Jersey 08807. |
| |
| |
The proxy statement and annual report to stockholders
are available at https://vynetherapeutics.com/investors-media/filings-financials/. |
| |
| GENERAL INFORMATION | | | | | | | |
| | | | | 2 | | | |
| | | | | 8 | | | |
| | | | | 12 | | | |
| | | | | 14 | | | |
| | | | | 15 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 36 | | | |
| | | | | 37 | | | |
| | | | | 37 | | | |
| | | | | 38 | | | |
| | | | | 43 | | | |
| | | | | 47 | | | |
| | | | | 47 | | | |
| | | | | 47 | | | |
| | | | | A-1 | | |
|
Director
|
| |
Age
|
| |
Position
|
| |
Director
Since |
| |||
|
Class I Directors whose terms expire at the 2025 Annual
Meeting |
| | | | |||||||||
|
Steven Basta
|
| |
58
|
| | Director | | | | | 2015 | | |
|
Anthony Bruno(1)(2)
|
| |
67
|
| | Director | | | | | 2020 | | |
|
Elisabeth Sandoval(2)(3)
|
| |
61
|
| | Director | | | | | 2019 | | |
|
Class II Director whose term expires at the Annual Meeting
|
| | | | | | | | | | | | |
|
Sharon Barbari (1)(2)(3)
|
| |
69
|
| | Director | | | | | 2020 | | |
|
Class III Directors whose terms expire at the 2024 Annual Meeting
|
| | | | |||||||||
|
David Domzalski
|
| |
57
|
| |
President, Chief Executive Officer
and Director |
| | | | 2020 | | |
|
Patrick LePore(1)(3)
|
| |
68
|
| | Lead Independent Director | | | | | 2020 | | |
| | |
Fiscal year ended December 31,
|
| |||||||||
| | |
2022
|
| |
2021
|
| ||||||
| | |
(in thousands of U.S. dollars)
|
| |||||||||
Audit fees(1)
|
| | | $ | 409 | | | | | $ | 1,050 | | |
All other fees
|
| | | | — | | | | | | 4 | | |
Total Fees
|
| | | $ | 409 | | | | | $ | 1,054 | | |
| | |
As of November 3,
2023 |
| |||
Total number of shares subject to all outstanding stock options
|
| | | | 209,537 | | |
Weighted-average exercise price of outstanding stock options
|
| | | $ | 137.56 | | |
Weighted-average remaining term of all outstanding stock options
|
| | | | 6.22 | | |
Total number of shares subject to all outstanding full value awards
|
| | | | 30,209 | | |
Total number of shares outstanding
|
| | | | 13,957,324 | | |
Per-share closing price of common stock as reported on Nasdaq Global Select Market
|
| | | $ | 3.03 | | |
| | |
Fiscal Year
|
| |||||||||||||||
| | |
2022
|
| |
2021
|
| |
2020(1)
|
| |||||||||
Total number of shares subject to stock options granted under all plans
|
| | | | 48,861 | | | | | | 93,689 | | | | | | 51,418 | | |
Total number of shares subject to time-based full value awards granted under all plans
|
| | | | 40,339 | | | | | | 53,934 | | | | | | 25,652 | | |
Total number of shares subject to performance-based full value awards earned under all plans
|
| | | | — | | | | | | — | | | | | | — | | |
Weighted-average number of shares outstanding
|
| | | | 3,186,361 | | | | | | 2,859,403 | | | | | | 1,800,975 | | |
Gross Burn Rate(2)
|
| | | | 2.8% | | | | | | 5.2% | | | | | | 4.3% | | |
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights and vesting of RSUs(1) |
| |
Weighted-average
exercise price of outstanding options, warrants and rights and weighted-average grant date price of RSUs |
| |
Number of securities
remaining available for future issuance under equity compensation plans(2) |
| |||||||||
Equity compensation plans approved by security
holders |
| | | | 313,403 | | | | | $ | 113.41 | | | | | | 188,611 | | |
Equity compensation plans not approved by
security holders |
| | | | — | | | | | $ | — | | | | | | — | | |
Total
|
| | | | 313,403 | | | | | $ | 113.41 | | | | | | 188,611 | | |
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating and
Corporate Governance |
| |||||||||
David Domzalski
|
| | | | — | | | | |
|
—
|
| | | |
|
—
|
| |
Sharon Barbari
|
| | |
|
X(1)
|
| | | |
|
X
|
| | | |
|
X
|
| |
Steven Basta
|
| | | | — | | | | |
|
—
|
| | | |
|
—
|
| |
Anthony Bruno
|
| | | | — | | | | |
|
X
|
| | | |
|
X(1)
|
| |
Patrick LePore
|
| | |
|
X
|
| | | |
|
—
|
| | | |
|
X
|
| |
Elisabeth Sandoval
|
| | | | X | | | | | | X(1) | | | | | | — | | |
| Gender Identity | | |
Female
|
| |
Male
|
|
| Number of Directors | | |
2
|
| |
4
|
|
| Demographic Background | | |
Hispanic or Latinx
|
| |
White
|
|
| Number of Directors | | |
1
|
| |
5
|
|
| Gender Identity | | |
Female
|
| |
Male
|
|
| Number of Directors | | |
2
|
| |
4
|
|
| Demographic Background | | |
Hispanic or Latinx
|
| |
White
|
|
| Number of Directors | | |
1
|
| |
5
|
|
Additional annual retainer fees for service as a member or chair of the following committees
(with chair fees inclusive of fees for service as a member) |
| |
Member
|
| |
Chair
|
| ||||||
Audit Committee
|
| | | $ | 10,000 | | | | | $ | 20,000 | | |
Compensation Committee
|
| | | $ | 7,500 | | | | | $ | 15,000 | | |
Nominating and Corporate Governance Committee
|
| | | $ | 5,000 | | | | | $ | 10,000 | | |
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Option Awards
($)(1)(2) |
| |
Total
Compensation ($) |
| |||||||||
Sharon Barbari
|
| | | | 72,500 | | | | | | 4,100 | | | | | | 76,600 | | |
Steven Basta
|
| | | | 40,000 | | | | | | 4,100 | | | | | | 44,100 | | |
Anthony Bruno
|
| | | | 57,500 | | | | | | 4,100 | | | | | | 61,600 | | |
Patrick LePore
|
| | | | 80,000 | | | | | | 4,100 | | | | | | 84,100 | | |
Elisabeth Sandoval
|
| | | | 65,000 | | | | | | 4,100 | | | | | | 69,100 | | |
Name
|
| |
Shares Underlying
Outstanding Options |
| |||
Sharon Barbari
|
| | | | 3,409 | | |
Steven Basta
|
| | | | 14,289 | | |
Anthony Bruno
|
| | | | 3,215 | | |
Patrick LePore
|
| | | | 2,903 | | |
Elisabeth Sandoval
|
| | | | 3,840 | | |
Name
|
| |
Age
|
| |
Position(s)
|
|
David Domzalski(1)
|
| | 57 | | | President, Chief Executive Officer and Director | |
Tyler Zeronda
|
| | 37 | | | Chief Financial Officer and Treasurer | |
Mutya Harsch
|
| | 49 | | | General Counsel, Chief Legal Officer and Secretary | |
Iain Stuart
|
| | 50 | | | Chief Scientific Officer | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Non-
equity Incentive Compensation ($)(1) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(2) |
| |
All Other
Compensation ($)(3) |
| |
Total
Compensation ($) |
| |||||||||||||||||||||
David Domzalski
President and Chief Executive Officer |
| | | | 2022 | | | | | | 637,560 | | | | | | 325,156 | | | | | | 190,504 | | | | | | 128,044 | | | | | | 12,200 | | | | | | 1,293,464 | | |
| | | 2021 | | | | | | 637,560 | | | | | | 242,910 | | | | | | 1,818,861(4) | | | | | | 2,141,994(4) | | | | | | 11,600 | | | | | | 4,852,925 | | | ||
Mutya Harsch
Chief Legal Officer, General Counsel and Secretary |
| | | | 2022 | | | | | | 422,172 | | | | | | 143,538 | | | | | | 45,750 | | | | | | 30,750 | | | | | | 12,200 | | | | | | 654,410 | | |
| | | 2021 | | | | | | 405,936 | | | | | | 142,007 | | | | | | 345,587(4) | | | | | | 406,976(4) | | | | | | 11,600 | | | | | | 1,312,106 | | | ||
Iain Stuart
Chief Scientific Officer |
| | | | 2022 | | | | | | 421,811 | | | | | | 143,415 | | | | | | 45,750 | | | | | | 30,750 | | | | | | 12,200 | | | | | | 653,926 | | |
| | | 2021 | | | | | | 405,576 | | | | | | 117,620 | | | | | | 345,587(4) | | | | | | 406,976(4) | | | | | | 11,600 | | | | | | 1,287,359 | | |
| | | | | | | | |
Option Awards
|
| |
Share Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Vesting
Commencement Date(1) |
| |
Number of
Securities Underlying Unexercised Options Exercisable |
| |
Number of
Securities Underlying Unexercised Options Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Shares That Have Not Vested (#) |
| |
Market Value
of Shares or Units of Shares That Have Not Vested(2) ($) |
| |||||||||||||||||||||
David Domzalski
|
| | | | 6/9/2014 | | | | | | 468 | | | | | | — | | | | | | 319.68 | | | | | | 6/9/2024 | | | | | | — | | | | | | — | | |
| | | 11/10/2015 | | | | | | 5,922 | | | | | | — | | | | | | 285.84 | | | | | | 11/10/2025 | | | | | | — | | | | | | — | | | ||
| | | 3/1/2016 | | | | | | 1,500 | | | | | | — | | | | | | 241.92 | | | | | | 3/1/2026 | | | | | | — | | | | | | — | | | ||
| | | 2/21/2017 | | | | | | 1,784 | | | | | | — | | | | | | 408.96 | | | | | | 2/21/2027 | | | | | | — | | | | | | — | | | ||
| | | 8/8/2017 | | | | | | 8,195 | | | | | | — | | | | | | 230.40 | | | | | | 8/8/2027 | | | | | | — | | | | | | — | | | ||
| | | 5/8/2018 | | | | | | 1,755 | | | | | | — | | | | | | 203.40 | | | | | | 5/8/2028 | | | | | | — | | | | | | — | | | ||
| | | 1/1/2019 | | | | | | 4,009 | | | | | | 267 | | | | | | 151.20 | | | | | | 1/1/2029 | | | | | | 114 | | | | | | 308 | | | ||
| | | 2/24/2020 | | | | | | 4,144 | | | | | | 1,880 | | | | | | 161.28 | | | | | | 2/24/2030 | | | | | | 805 | | | | | | 2,174 | | | ||
| | | 5/6/2020 | | | | | | 5,904 | | | | | | 3,539 | | | | | | 140.40 | | | | | | 5/6/2030 | | | | | | 3,540 | | | | | | 9,558 | | | ||
| | | 2/22/2021 | | | | | | 8,721 | | | | | | 11,208 | | | | | | 149.94 | | | | | | 2/22/2031 | | | | | | 4,803 | | | | | | 12,968 | | | ||
| | | 9/2/2021(3) | | | | | | 11,123 | | | | | | 6,672 | | | | | | 30.24 | | | | | | 9/2/2031 | | | | | | 17,795 | | | | | | 48,047 | | | ||
| | | 3/17/2022 | | | | | | — | | | | | | 17,349 | | | | | | 10.98 | | | | | | 3/17/2032 | | | | | | 17,350 | | | | | | 46,845 | | | ||
Mutya Harsch
|
| | | | 2/27/2018 | | | | | | 1,250 | | | | | | — | | | | | | 254.16 | | | | | | 2/27/2028 | | | | | | — | | | | | | — | | |
| | | /1/2019 | | | | | | 1,649 | | | | | | 109 | | | | | | 151.20 | | | | | | 1/1/2029 | | | | | | 46 | | | | | | 124 | | | ||
| | | 2/24/2020 | | | | | | 1,659 | | | | | | 750 | | | | | | 161.28 | | | | | | 2/24/2030 | | | | | | 320 | | | | | | 864 | | | ||
| | | 5/6/2020 | | | | | | 1,303 | | | | | | 779 | | | | | | 140.40 | | | | | | 5/6/2030 | | | | | | 780 | | | | | | 2,106 | | | ||
| | | 2/22/2021 | | | | | | 1,658 | | | | | | 2,127 | | | | | | 149.94 | | | | | | 2/22/2031 | | | | | | 910 | | | | | | 2,457 | | | ||
| | | 9/2/2021(3) | | | | | | 2,114 | | | | | | 1,266 | | | | | | 30.24 | | | | | | 9/2/2031 | | | | | | 3,381 | | | | | | 9,129 | | | ||
| | | 3/17/2022 | | | | | | — | | | | | | 4,165 | | | | | | 10.98 | | | | | | 3/17/2032 | | | | | | 4,166 | | | | | | 11,248 | | | ||
Iain Stuart
|
| | | | 11/15/2016 | | | | | | 1,000 | | | | | | — | | | | | | 342.00 | | | | | | 11/15/2026 | | | | | | — | | | | | | — | | |
| | | 8/8/2017 | | | | | | 325 | | | | | | — | | | | | | 216.00 | | | | | | 8/8/2027 | | | | | | — | | | | | | — | | | ||
| | | 2/27/2018 | | | | | | 750 | | | | | | — | | | | | | 254.16 | | | | | | 2/27/2028 | | | | | | — | | | | | | — | | | ||
| | | 1/01/2019 | | | | | | 1,782 | | | | | | 118 | | | | | | 151.20 | | | | | | 1/1/2029 | | | | | | 50 | | | | | | 135 | | | ||
| | | 2/24/2020 | | | | | | 1,659 | | | | | | 750 | | | | | | 161.28 | | | | | | 2/24/2030 | | | | | | 320 | | | | | | 864 | | | ||
| | | 5/06/2020 | | | | | | 979 | | | | | | 582 | | | | | | 140.40 | | | | | | 5/6/2030 | | | | | | 583 | | | | | | 1,574 | | | ||
| | | 2/22/2021 | | | | | | 1,658 | | | | | | 2,127 | | | | | | 149.94 | | | | | | 2/22/2031 | | | | | | 910 | | | | | | 2,457 | | | ||
| | | 9/2/2021(3) | | | | | | 2,114 | | | | | | 1,266 | | | | | | 30.24 | | | | | | 9/2/2031 | | | | | | 3,381 | | | | | | 9,129 | | | ||
| | | 3/17/2022 | | | | | | — | | | | | | 4,166 | | | | | | 10.98 | | | | | | 3/17/2032 | | | | | | 4,166 | | | | | | 11,248 | | |
Name of Beneficial Owner
|
| |
Number of
Shares Owned and Nature of Beneficial Ownership |
| |
Percent of Class
|
| ||||||
5% and Greater Stockholders: | | | | | | | | | | | | | |
AI Biotechnology LLC(1)
|
| | | | 1,394,336 | | | | | | 9.99% | | |
Cormorant Global Healthcare Master Fund, LP(2)
|
| | | | 1,394,336 | | | | | | 9.99% | | |
Eventide Healthcare Innovation Fund I LP(3)
|
| | | | 1,394,336 | | | | | | 9.99% | | |
Citadel CEMF Investments Ltd.(4)
|
| | | | 1,181,088 | | | | | | 8.46% | | |
Soleus Capital Master Fund, L.P.(5)
|
| | | | 890,868 | | | | | | 6.38% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
David Domzalski(6)
|
| | | | 112,764 | | | | | | * | | |
Mutya Harsch(7)
|
| | | | 36,327 | | | | | | * | | |
Iain Stuart(8)
|
| | | | 22,718 | | | | | | * | | |
Steven Basta(9)
|
| | | | 21,735 | | | | | | * | | |
Sharon Barbari(10)
|
| | | | 4,448 | | | | | | * | | |
Name of Beneficial Owner
|
| |
Number of
Shares Owned and Nature of Beneficial Ownership |
| |
Percent of Class
|
| ||||||
Anthony Bruno(11)
|
| | | | 5,088 | | | | | | * | | |
Patrick LePore(12)
|
| | | | 26,373 | | | | | | * | | |
Elisabeth Sandoval(13)
|
| | | | 3,837 | | | | | | * | | |
All current directors and executive officers as a group (9 persons)(14)
|
| | | | 246,139 | | | | | | 1.8% | | |
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights and vesting of RSUs(1) |
| |
Weighted-average
exercise price of outstanding options, warrants and rights and weighted- average grant date price of RSUs |
| |
Number of securities
remaining available for future issuance under equity compensation plans(2) |
| |||||||||
Equity compensation plans approved by security
holders |
| | | | 313,403 | | | | | $ | 113.41 | | | | | | 188,611 | | |
Equity compensation plans not approved by
security holders |
| | | | — | | | | | $ | — | | | | | | — | | |
Total
|
| | | | 313,403 | | | | | $ | 113.41 | | | | | | 188,611 | | |
| By Order of the Board of Directors | |
|
![]() |
|
|
David Domzalski
President and Chief Executive Officer |
|
| November 13, 2023 | |
1 Year VYNE Therapeutics Chart |
1 Month VYNE Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions